---
id: 058
title: Polymyxins (Colistin and Polymyxin B) Mechanism and Spectrum
category: antimicrobials
subcategory: polymyxins
tags: [colistin, polymyxin-B, carbapenem-resistant, MDR, gram-negative, last-resort]
difficulty: medium
---

## Question

What is the mechanism of action and spectrum for polymyxins (colistin and polymyxin B)? Use the **"LAST-LINE for MDR Gram-negatives"** mnemonic.

## Answer

### **"LAST-LINE for MDR Gram-negatives" Mnemonic:**

**LAST-LINE:**
- **L**ast resort antibiotic
- **A**ttacks LPS (lipopolysaccharide)
- **S**alvage therapy for CRE, MDR *Pseudomonas*, *Acinetobacter*
- **T**oxic (nephrotoxic 40-60%)

**MDR Gram-negatives:**
- **M**DR *Pseudomonas aeruginosa*
- **D**isplaces Ca²⁺/Mg²⁺ from outer membrane
- **R**esistant Enterobacterales (CRE)

**Gram-negatives:**
- **G**ram-negative ONLY (no Gram-positive activity)
- **R**esistant *Acinetobacter baumannii*
- **A**ctions: membrane disruption
- **M**embrane permeabilization → cell death

### **Mechanism of Action:**

**Step 1: Electrostatic Binding**
- Polymyxins are **cationic cyclic decapeptides**
- Bind to **anionic LPS** on Gram-negative outer membrane
- Displaces **Ca²⁺ and Mg²⁺** (normally stabilize LPS)

**Step 2: Membrane Disruption**
- Lipophilic tail inserts into membrane
- Increases membrane permeability
- Leakage of cell contents

**Step 3: Additional Killing**
- **Fenton reaction** → oxidative damage to DNA, proteins, lipids
- **Bactericidal** effect

### **Spectrum of Activity:**

| Organism | Activity | Notes |
|----------|----------|-------|
| ***Pseudomonas aeruginosa*** (MDR) | Excellent | Including carbapenem-resistant |
| ***Acinetobacter baumannii*** (MDR) | Excellent | Including carbapenem-resistant |
| **CRE (carbapenem-resistant Enterobacterales)** | Excellent | *E. coli*, *Klebsiella*, *Enterobacter* |
| ***Klebsiella pneumoniae*** (MDR) | Excellent | Including KPC producers |
| **Stenotrophomonas maltophilia** | Variable | Often resistant |
| **Gram-positives** | **NO** | Zero activity |
| **Anaerobes** | **NO** | No activity |
| ***Proteus spp.*** | **NO** | Intrinsically resistant |
| ***Serratia spp.*** | **NO** | Intrinsically resistant |
| ***Burkholderia cepacia*** | Variable | Often resistant |

## Key Points

### **Clinical Indications (Last Resort Only):**

| Infection | Use | Notes |
|-----------|-----|-------|
| **CRE infections** | Salvage therapy | Combination preferred |
| **MDR *Pseudomonas*** | Salvage therapy | Resistance increasing |
| **MDR *Acinetobacter*** | Salvage therapy | Common in HAP/VAP |
| **Carbapenem-resistant HAP/VAP** | Last resort | High toxicity |

**FDA-Approved Indication:**
- Colistin: NOT FDA approved (available as colistimethate sodium - prodrug)
- Polymyxin B: FDA approved for serious infections caused by susceptible Gram-negative bacteria

### **Two Formulations:**

#### **Colistin (Colistimethate Sodium - CMS):**
- **Prodrug** → converted to active colistin in vivo
- Less toxic during infusion (inactive form)
- Unpredictable conversion → variable levels
- **Dosing:** 2.5-5 mg/kg/day IV (divided BID-QID) based on colistin base activity (CBA)

#### **Polymyxin B:**
- **Active drug** (not prodrug)
- More predictable pharmacokinetics
- Dosed in units: **15,000-25,000 units/kg/day IV divided q12h**
- 1 mg polymyxin B ≈ 10,000 units

### **Key Differences: Colistin vs Polymyxin B:**

| Feature | Colistin (CMS) | Polymyxin B |
|---------|----------------|-------------|
| **Formulation** | Prodrug | Active drug |
| **PK predictability** | Variable (prodrug conversion) | More predictable |
| **Dosing complexity** | More complex (CBA units) | Simpler (weight-based) |
| **Nephrotoxicity** | 40-52% | 35-45% (possibly lower) |
| **Neurotoxicity** | 0-7% | 0-7% (possibly higher) |
| **Clinical experience** | More data | Less data historically |

### **Resistance Mechanisms:**

**MCR genes** (mobile colistin resistance):
- **mcr-1** through **mcr-10** genes
- **Plasmid-mediated** → rapidly spreading
- Modifies LPS with phosphoethanolamine → reduces negative charge
- Reduces polymyxin binding

**Chromosomal mutations:**
- *pmrAB*, *phoPQ* genes → LPS modification
- Reduces electrostatic attraction

### **Clinical Pearls:**
- **Last resort** antibiotic (use only when no alternatives)
- **Always use in combination** (reduce resistance, improve outcomes)
- Common combinations: Polymyxin + carbapenem, + tigecycline, + aminoglycoside
- **Resistance increasing** (mcr genes spreading globally)
- **Toxicity high** (nephrotoxicity 40-60%, limits use)

## Sources

- [Frontiers Pharmacology 2024: Polymyxins Recent Advances]
- [PMC9759378: Colistin Resistance and Management]
- [PMC8406936: Intrinsic and Acquired Colistin Resistance]
- [BMC Infect Dis 2024: Polymyxin B vs Colistin Comparison]

## Media

N/A
